A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials.
Consider a pharmaceutical trial where the consequences of different decisions are expressed on a financial scale. The efficacy of the new drug under consideration has a prior distribution obtained from the underlying biological process, animal experiments, clinical experience, and so forth. Berry and Ho (Biometrics 44, 219-227) show how these components are used to establish an optimal (Bayes) sequential testing procedure, assuming a known constant sample size at each decision point. We show in this article how it is also possible to optimize further, with respect to the sample-size rule. This component of the design, which is missing from most sequential procedures, has the potential to yield considerably larger expected net gains (equivalently, considerably smaller Bayes risks).
Cressie
N
N
Department of Statistics, Iowa State University, Ames 50011.
Biele
J
J
D000818:Animals; D001499:Bayes Theorem; D001699:Biometry; D002986:Clinical Trials as Topic / Q000379:methods*; D018849:Controlled Clinical Trials as Topic / Q000379:methods*; D004358:Drug Therapy; D006801:Humans; D008433:Mathematics